Clinical utility and tolerability of linagliptin in diabetic patients

Lauralee Gordon Maxwell
M Shawn McFarland

1 Department of Veterans Affairs, TN Valley Healthcare System, Murfreesboro, 2 The University of Tennessee Department of Clinical Pharmacy, Memphis, TN, USA

Background: The purpose of this paper is to review the efficacy, safety, and tolerability of linagliptin in the management of hyperglycemia in adults with type 2 diabetes mellitus.

Methods: A Medline search was performed using the keywords “linagliptin” and “type 2 diabetes” for articles published September 2010 through July 2012. The literature search was limited by the following criteria: articles’ publication in the English language, clinical trials, randomized controlled trials, and research conducted in humans.

Results: A review of the data for linagliptin in the treatment of type 2 diabetes as monotherapy or in combination with other antidiabetic therapies suggests clinical efficacy in terms of reductions in glycosylated hemoglobin, fasting plasma glucose, and postprandial glucose. Most adverse events with linagliptin are considered to be mild to moderate in nature. Although linagliptin therapy may offer a low risk of hypoglycemia, the risk increases when it is used in combination with insulin secretagogues. Linagliptin can generally be considered weight neutral, but a weight increase was observed when linagliptin was used in combination with a thiazolidinedione.

Conclusion: Linagliptin is a once-daily oral medication used for the treatment of type 2 diabetes. The use of linagliptin as monotherapy or in combination with metformin, sulfonylureas, or pioglitazone led to improvement in glycemic control and was well tolerated by most patients.

Keywords: type 2 diabetes, linagliptin, dipeptidyl peptidase-4 inhibitor

Introduction

Linagliptin (Tradjenta®, Boehringer Ingelheim, Ridgefield, CT, USA) is a newly approved medication for the treatment of type 2 diabetes mellitus. This agent is a potent inhibitor of the serine protease enzyme, dipeptidyl peptidase-4 (DPP-4), which is responsible for rapid degradation of two incretin hormones, glucagon-like-peptide 1 (GLP-1) and glucose insulintropic polypeptide (GIP). GLP-1 and GIP have distinct physiologic actions in the regulation of glucose that would make their augmentation attractive in the patient with type 2 diabetes due to a propensity to achieve decreased levels of both hormones.

GLP-1 is secreted from intestine endocrine L-cells in response to glucose and is responsible for stimulation of insulin release from the pancreas in a glucose-dependent manner. GLP-1 inhibits the release of glucagon, thereby decreasing hepatic gluconeogenesis and insulin inhibition. GLP-1 decreases gastric emptying, delaying arrival of glucose into the vasculature, and works centrally in the brain by increasing satiety with a decrease in food intake. Lastly, GLP-1 can increase β-cell mass by decreasing apoptosis and by increasing proliferation and neogenesis of β-cells. However, this has only been shown in animal models, with no evidence of this noted in humans.
as yet. GIP is secreted from the K-cells of the intestine wall, stimulates insulin secretion from the pancreas, and has been shown to decrease cellular death and increase regeneration of β-cells.

Linagliptin has been shown to be a potent long-acting DPP-4 inhibitor. An in vitro study showed that linagliptin inhibited DPP-4 with a 50% inhibition concentration (IC$_{50}$) of about 1 nM, compared with sitagliptin (19 nM), alogliptin (24 nM), saxagliptin (50 nM), and vidagliptin (62 nM). Linagliptin has an elimination half-life of 131 hours, and achieves steady-state concentrations after three doses of 5 mg daily. Linagliptin has also been shown to inhibit DPP-4 activity by more than 80% over 24 hours. The presence of these characteristics allows for once-daily oral dosing. Linagliptin undergoes primarily hepatic elimination, with approximately 85% of the drug excreted unchanged in the feces. Despite having a predominately hepatic route of elimination, the main metabolite is pharmacologically inactive. The overall pharmacokinetic profile of linagliptin may avoid the need to adjust the dose in patients with renal or hepatic impairment. The recommendations provided by the package insert indicate no dose adjustments are required for renal or hepatic impairment.

Multiple therapies have now been introduced to the market that target the incretin hormone system. Current guidelines recommend that these treatments be considered as part of a “patient-centered approach” and be used as a component of a two-drug or three-drug regimen in conjunction with metformin if a patient does not meet their individualized glycosylated hemoglobin (HbA1c) goal.

Materials and methods
A Medline search was performed using the keywords “linagliptin”, “DPP-4 inhibitor”, and “type 2 diabetes” for articles published through July 2012. The literature search was limited by the following criteria: publication in the English language, clinical trials, randomized controlled trials, and research conducted in humans (Figure 1). Here we summarize the available data with a focus on the clinical utility and tolerability of linagliptin.

Results
Linagliptin monotherapy
This Phase IIa study conducted by Forst et al followed a randomized, double-blind, within-dose level, parallel, placebo-controlled design and examined the pharmacokinetic and pharmacodynamic properties of linagliptin in patients with type 2 diabetes after 4 weeks of treatment. Participants enrolled in this study were either treatment-naïve or had received one or two oral antidiabetic therapies other than a thiazolidinedione. Participants were 21–70 (median 62) years of age, had a body mass index of 18.5–35 kg/m$^2$, and had an HbA1c ≤ 8.5% for treatment-naïve and/or one oral antidiabetic therapy, and ≤8.0% for patients treated with two
oral antidiabetic therapies. The HbA1c for the total cohort of 77 patients was 7.0%. In participants receiving an oral antidiabetic therapy, a washout period of 14 days was required. Eligible patients were randomly assigned to receive linagliptin 2.5 mg (n = 26), 5 mg (n = 16), 10 mg (n = 19), or placebo (n = 16). Statistically significant decreases in mean HbA1c from baseline were observed at the end of the 4-week period for all the linagliptin groups compared with placebo. The placebo-corrected mean change in HbA1c was −0.31% for linagliptin 2.5 mg, −0.37% for linagliptin 5 mg, and −0.28% for linagliptin 10 mg (P < 0.025). Statistically significant decreases in fasting plasma glucose and postprandial plasma glucose were also observed from baseline to the end of the study period for all linagliptin doses (see Table 1).

Another randomized, double-blind, parallel-group study comparing treatment with either linagliptin 5 mg or placebo for 24 weeks in patients with type 2 diabetes was conducted by Del Prato et al.12 Patients were aged 18–80 (mean 55.7) years with a body mass index ≤ 40 kg/m², and were either treatment-naïve or previously treated with one oral antidiabetic therapy other than a thiazolidinedione. Pretreated patients underwent a 6-week washout period, with the last 2 weeks being an open-label placebo run-in. Treatment-naïve patients entered directly into the 2-week placebo run-in period. HbA1c levels had to be between 6.5% and 9.0% in non-treatment-naïve patients or between 7.0% and 10% in treatment-naïve patients. Eligible patients were then randomized to receive treatment with linagliptin 5 mg or placebo for 24 weeks. The adjusted mean difference in the change of HbA1c comparing linagliptin and placebo was −0.69% (P < 0.0001). The primary endpoint was adjusted for baseline HbA1c and previous oral antidiabetic therapy. Treatment with linagliptin also resulted in significant decreases in fasting plasma glucose and postprandial plasma glucose compared with placebo (see Table 1).

Combination therapy
Linagliptin versus placebo as add-on therapy to metformin
Taskinen et al performed a randomized, double-blind, placebo-controlled, multicenter, parallel-group study in 701 patients with type 2 diabetes aged 18–80 years.13 Subjects included had a mean age of 56.5 years, a body mass index ≤ 40 kg/m², and a mean baseline HbA1c of 8.1%. Subjects eligible for inclusion needed to have received metformin at a dose ≥ 1500 mg/day (or the maximum tolerated dose) and not more than one other oral antidiabetic therapy. In patients who had previously been treated with metformin monotherapy, HbA1c had to be 7.0%–10.0% at screening; for patients treated with an additional medication, A1c had to be 6.5%–9.0%. Patients taking antidiabetic therapy in addition to metformin were instructed to stop the medication and then underwent a 6-week washout period that included an open-label placebo run-in phase in the last 2 weeks. For patients taking metformin monotherapy at enrollment, only the 2-week run-in phase was required. All eligible patients continued their usual dose of metformin and were then randomized to treatment with either linagliptin 5 mg once daily or placebo for 24 weeks. The primary endpoint was the change from baseline HbA1c, adjusted for baseline HbA1c and the use of monotherapy versus combination therapy at enrollment, after 24 weeks of treatment. At the end of the study, linagliptin reduced the mean HbA1c level by 0.49%, whereas HbA1c in the placebo group rose by 0.15% (P < 0.0001). The placebo-corrected reduction in HbA1c was 0.64%. Linagliptin also led to significant reductions versus placebo in both fasting plasma glucose and postprandial plasma glucose (P < 0.0001, see Table 2).

Linagliptin + metformin versus linagliptin alone, metformin alone, and placebo
Haak et al conducted a 24-week, randomized, double-blind, placebo-controlled Phase III trial in 791 patients who were either treatment-naïve or had been treated with one other antidiabetic therapy.15 Eligible patients were 18–80 years of age, had a diagnosis of type 2 diabetes, and had a body mass index of ≤ 40 kg/m². In treatment-naïve participants, HbA1c had to be ≥7.5% and <11%, and for patients pretreated with one antidiabetic therapy had to be ≥7.0% to ≤10.5%. Patients pretreated with one antidiabetic therapy entered a 4-week washout period followed by a 2-week placebo run-in period that all patients participated in. Subjects were then treated for 24 weeks with one of two free combinations of linagliptin (linagliptin 2.5 mg twice daily + metformin 500 mg twice daily or 1000 mg twice daily) or placebo, linagliptin 5 mg once daily, metformin 500 mg twice daily, or metformin 1000 mg twice daily monotherapy. The primary endpoint was change in HbA1c from baseline to 24 weeks of treatment, adjusted for baseline HbA1c and previous oral antidiabetic therapy. Mean baseline HbA1c values were similar for all treatment groups, with an overall mean of 8.7%. The adjusted placebo-corrected mean (95% confidence interval) changes in HbA1c were −1.7% (−2.0%, −1.4%) for linagliptin + metformin 1000 mg; −1.3% (−1.6, −1.1) for linagliptin + metformin 500 mg; −1.2% (−1.5%, −0.9%) for metformin 1000 mg; −0.8% (−1.0, −0.5) for
<table>
<thead>
<tr>
<th>Authors and study design</th>
<th>Dose (Patients, n)</th>
<th>Study parameters</th>
<th>Efficacy results</th>
<th>Tolerability results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forst et al11 R, DB, PG, PC Patients with type 2 diabetes not controlled by up to two ADT (excluding TZD) or treatment-naïve</td>
<td>Linagliptin 2.5 mg (n = 26) Linagliptin 5 mg (n = 16) Linagliptin 10 mg (n = 19) Placebo: n = 16 Total: 4 weeks</td>
<td>Primary: safety and tolerability Secondary:</td>
<td>At week 4:</td>
<td>Most common: Nasopharyngitis (5 patients or 6%) Back pain (4 patients or 5%) The incidence was similar between placebo-treated and linagliptin-treated patients No subjects showed signs or symptoms of hypoglycemia</td>
</tr>
<tr>
<td>2.5 mg</td>
<td>−0.31a,b</td>
<td>−19.2a,b</td>
<td>−32.4b</td>
<td></td>
</tr>
<tr>
<td>5 mg</td>
<td>−0.37a,b</td>
<td>−21.4a,b</td>
<td>−52.5b</td>
<td></td>
</tr>
<tr>
<td>10 mg</td>
<td>−0.28a,b</td>
<td>−16.6a,b</td>
<td>−27.2b</td>
<td></td>
</tr>
<tr>
<td>Del Prato et al12 R, DB, PC, PG Patients with type 2 diabetes not controlled by one ADT (excluding TZD) or were treatment-naïve</td>
<td>Linagliptin 5 mg (n = 336) Placebo (n = 167) Total: 24 weeks</td>
<td>Primary: A1c Secondary: A1c &lt; 7.0% and &lt;6.5% A1c lowered by &gt;0.5% FPG PPG Other: body weight</td>
<td>At week 24:</td>
<td>Most common: Hyperglycemia (8.6% linagliptin versus 22.8% placebo) Nasopharyngitis (3.9% linagliptin versus 4.2% placebo) One patient in each group experienced hypoglycemia Body weight did not differ significantly from baseline in either group at the end of the study period</td>
</tr>
<tr>
<td>5 mg</td>
<td>−0.69a</td>
<td>−23.4b</td>
<td>−57.7b</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: A1c, glycosylated hemoglobin; ADT, antidiabetic therapy; DB, double-blind; FPG, fasting plasma glucose; MC, multicenter; PG, parallel-group; PC, placebo-controlled; PPG, postprandial plasma glucose; R, randomized; TZD, thiazolidinediones.
metformin 500 mg; and −0.6% (−0.9%, −0.3%) for linagliptin monotherapy (all \( P < 0.0001 \)). Significant reductions in fasting plasma glucose from baseline to the end of the study period were seen with combination therapies relative to metformin monotherapy. The placebo-corrected changes in fasting plasma glucose from baseline were also statistically significant for each group. This study did not assess changes in postprandial plasma glucose (see Table 2).

**Linagliptin versus placebo in combination with metformin and sulfonylurea**

This randomized, placebo-controlled, double-blind, parallel-group study enrolled subjects with type 2 diabetes receiving metformin \( \geq 1500 \) mg/day (or the maximum tolerated dose) and the maximum tolerated dose of sulfonylurea.\(^\text{16}\) Patients were 18–80 (mean 58.1) years of age, with a body mass index \( \leq 40 \) kg/m\(^2\) and HbA1c \( \geq 7.0\% \) and \( \leq 10.0\% \) (mean 8.14%). Following a 2-week placebo run-in, a total of 1055 participants were randomized to treatment with linagliptin 5 mg once daily or placebo, in addition to the established background therapy of metformin in combination with a sulfonylurea. The primary endpoint was the change in HbA1c levels between baseline and 24 weeks, stratified by baseline HbA1c value. After 24 weeks, linagliptin was superior to placebo for the adjusted mean change in HbA1c from baseline. The linagliptin placebo-corrected adjusted mean change from baseline was −0.62% (\( P < 0.0001 \)). Linagliptin also produced greater reductions in fasting plasma glucose than placebo at week 24 (\( P < 0.0001 \), see Table 2).

**Linagliptin versus glimepiride in combination with metformin**

This randomized, double-blind, parallel-group, active-controlled, noninferiority trial was conducted by Gallwitz et al in 1519 patients with type 2 diabetes, aged 18–80 years, and a body mass index of \( \leq 40 \) kg/m\(^2\).\(^\text{17}\) Eligible subjects were receiving metformin 1500 mg/day (or the maximum tolerated dose) alone with an HbA1c of 6.5%–10.0% or 6.0%–9.0% on metformin and one other oral antidiabetic therapy. Mean baseline HbA1c and age were 7.7% and 59.8 years in each group, respectively. Participants receiving metformin and one additional antidiabetic therapy entered a 6-week washout period followed by a 2-week open-label placebo run-in. Those receiving metformin monotherapy entered directly into a 2-week, open-label, placebo run-in period. Subjects who met the inclusion criteria were then randomly assigned to treatment with linagliptin 5 mg once daily or glimepiride at an initial dose of 1 mg daily added to the current dose of metformin. The primary endpoint was the change in HbA1c from baseline to week 104, and was stratified by baseline HbA1c and previous antidiabetic therapy use. After 2 years of treatment, linagliptin was noninferior to glimepiride in reducing HbA1c. Adjusted mean changes were −0.16% with linagliptin and −0.36% with glimepiride. The difference between the treatment groups met the noninferiority criteria and was 0.20% (\( P < 0.125 \)). As add-on to metformin, both linagliptin and glimepiride caused significant reductions in fasting plasma glucose and postprandial plasma glucose. The treatment differences for reductions in fasting and postprandial plasma glucose, respectively, were 6.31 mg/dL (\( P = 0.012 \)) and 9.73 mg/dL (\( P = 0.0918 \), see Table 2).

The 12-week, multicenter, randomized, double-blind, placebo-controlled, five parallel-group study conducted by Forst et al included patients with type 2 diabetes aged 21–75 (mean 60) years with a body mass index of 25–40 kg/m\(^2\).\(^\text{14}\) Patients were eligible if they were pretreated with metformin alone (baseline HbA1c levels had to be 7.5%–10%) or treated with metformin and one other oral antidiabetic therapy other than a thiazolidinedione (baseline HbA1c levels had to be 7.0%–9.0%). Eligible patients who had already received metformin monotherapy entered a 2-week open-label run-in phase. Patients who received metformin plus one other antidiabetic therapy entered a 6-week washout period, with the last 2 weeks being an open-label run-in phase. Three doses of linagliptin (1, 5, and 10 mg once daily) were explored when added to metformin. There was also an open-label treatment arm where patients were randomized to receive glimepiride (1, 2, or 3 mg once daily) as add-on therapy to metformin. The mean placebo-corrected lowering of HbA1c levels was 0.39% for linagliptin 1 mg (\( P = 0.005 \)), 0.75% for 5 mg (\( P < 0.001 \)), and 0.73% for 10 mg (\( P < 0.001 \)). The change in mean placebo-corrected HbA1c from baseline was −0.90% for glimepiride. The reduction in HbA1c with open-label glimepiride was numerically greater versus linagliptin, but not statistically significant. Fasting plasma glucose reductions were also found to be significantly greater with all doses of linagliptin than with placebo at week 12. Postprandial plasma glucose changes were not addressed in this study (see Table 2).

**Linagliptin versus placebo as add-on to pioglitazone therapy**

This randomized, double-blind, placebo-controlled, multicenter, parallel-group study was conducted by Gomis et al in 389 patients with type 2 diabetes and aged 18–80 (mean 57.5) years.\(^\text{18}\) At baseline, the patients had HbA1c
Table 2  Efficacy and safety of linagliptin in combination with other ADTs for the treatment of type 2 diabetes

<table>
<thead>
<tr>
<th>Authors and study design</th>
<th>Dose, patients (n)</th>
<th>Study parameters</th>
</tr>
</thead>
</table>
| **Taskinen et al**<sup>13</sup>  
R, DB, PC, PG  
Patients with uncontrolled type 2 diabetes receiving maximum tolerated dose metformin and not more than one other ADT | Linagliptin 5 mg (n = 524) + metformin  
Placebo (n = 177) + metformin  
Total: 24 weeks | Primary:  
A1c  
Secondary:  
Body weight  
FPG  
PPG  
A1c < 7.0% and <6.5%  
A1c lowered by >0.5% |
| **Forst et al**<sup>14</sup>  
R, DB, PC, PG  
Patients with type 2 diabetes not controlled on metformin alone or with metformin and one other ADT (except TZD) | Linagliptin 1 mg (n = 65) + metformin  
Linagliptin 5 mg (n = 66) + metformin  
Linagliptin 10 mg (n = 66) + metformin  
Glimepiride (n = 65) + metformin  
Placebo (n = 71) + metformin  
Total: 12 weeks | Primary:  
A1c  
Secondary:  
Body weight |
| **Haak et al**<sup>15</sup>  
R, PC, DB, PG  
Patients with type 2 diabetes not controlled who were either treatment-naïve or had been treated with one other ADT | Linagliptin 2.5 mg BID + metformin 500 mg BID (n = 143)  
Linagliptin 2.5 mg BID + metformin 1000 mg BID (n = 143)  
Linagliptin 5 mg daily (n = 142)  
Metformin 500 mg BID (n = 144)  
Metformin 1000 mg BID (n = 147)  
Placebo (n = 72)  
Total: 24 weeks | Primary:  
A1c  
Secondary:  
Body weight |
| **Owens et al**<sup>16</sup>  
R, PC, DB, PG  
Patients with type 2 diabetes not controlled with metformin plus a sulfonylurea | Linagliptin 5 mg daily + metformin + sulfonylurea (n = 792)  
Placebo + metformin + sulfonylurea (n = 263)  
Total: 24 weeks | Primary:  
A1c  
Secondary:  
Body weight |
Efficacy results

At week 24:

<table>
<thead>
<tr>
<th>A1c change (%)</th>
<th>FPG change (mg/dL)</th>
<th>PPG change (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Linagliptin 5 mg</strong></td>
<td>–0.64ab</td>
<td>–21.62ab</td>
</tr>
</tbody>
</table>

Notes: *P < 0.00001; †placebo-corrected.

Among patients with a baseline A1c ≥ 7%, 26% of individuals treated with linagliptin versus 9% of those in the placebo group achieved A1c < 7% at 24 weeks (P = 0.0001). Similarly, in those patients with a baseline HbA1c ≥ 6.5%, 10% with linagliptin versus 2% with placebo achieved A1c < 6.5% at 24 weeks (P = 0.0016).

The percentage of patients achieving an A1c reduction ≥ 0.5% at 24 weeks was 50% with linagliptin and 22% with placebo (P < 0.0001).

At week 12:

<table>
<thead>
<tr>
<th>A1c change (%)</th>
<th>FPG change (mg/dL)</th>
<th>Body weight change (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mg</td>
<td>–0.39a</td>
<td>–19.8a</td>
</tr>
<tr>
<td>5 mg</td>
<td>–0.75a</td>
<td>–34.2a</td>
</tr>
<tr>
<td>10 mg</td>
<td>–0.73a</td>
<td>–30.6a</td>
</tr>
<tr>
<td>Glimepiride</td>
<td>–0.90a</td>
<td>–1.27</td>
</tr>
</tbody>
</table>

Notes: *P = 0.005; †P < 0.001; ††P < 0.0001; †‡P = 0.002; †††placebo-corrected.

A greater proportion of patients who received linagliptin (43.8%–53.2%) showed reductions in A1c ≥ 0.3% versus placebo at 12.9%. Only 1.4% of patients in the placebo group achieved A1c < 7% versus 15%–21% of the patients who received linagliptin therapy.

At week 24:

<table>
<thead>
<tr>
<th>A1c change (%)</th>
<th>FPG change (mg/dL)</th>
<th>Body weight change (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LIN 2.5 mg + MD MET 1000 mg</strong></td>
<td>–1.7ab</td>
<td>–59.46ab</td>
</tr>
<tr>
<td><strong>LIN 2.5 mg + MET 500 mg</strong></td>
<td>–1.3ab</td>
<td>–43.24ab</td>
</tr>
<tr>
<td><strong>MET 1000 mg</strong></td>
<td>–1.2ab</td>
<td>–41.44ab</td>
</tr>
<tr>
<td><strong>MET 500 mg</strong></td>
<td>–0.8ab</td>
<td>–25.23ab</td>
</tr>
<tr>
<td><strong>Linagliptin 5 mg</strong></td>
<td>–0.6ab</td>
<td>–18.02ab</td>
</tr>
</tbody>
</table>

Placebo N/A N/A –0.7

Notes: *Placebo-corrected; †P < 0.0001.

At week 24:

<table>
<thead>
<tr>
<th>A1c change (%)</th>
<th>FPG change (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Linagliptin</strong></td>
<td>–0.62ab</td>
</tr>
</tbody>
</table>

Notes: *Placebo-corrected; †P < 0.0001.

Among patients with a baseline A1c ≥ 7%, 29.2% of individuals treated with linagliptin versus 8.1% of those in the placebo group achieved A1c < 7% at 24 weeks (P < 0.0001). The percentage of patients achieving an A1c reduction ≥ 0.5% at 24 weeks was 58.2% with linagliptin and 30.2% with placebo.

Tolerability results

Most common:
- Hyperglycemia (5.2% linagliptin versus 14.7% placebo)
- Nasopharyngitis (5.2% linagliptin versus 5.1% placebo)
- Minor hypoglycemia (0.6% linagliptin versus 2.3% placebo)

No major hypoglycemia events

Body weight did not differ significantly from baseline in either group (−0.5 kg placebo; −0.4 kg linagliptin).

Most common:
- Nasopharyngitis (reported in 10%, 6%, 8%, 8%, 6% for placebo, 1 mg, 5 mg, 10 mg and glimepiride, respectively)
- Diarrhea (reported in 4%, 2%, 3%, 3%, 5% for placebo, 1 mg, 5 mg, 10 mg, and glimepiride respectively)
- Nausea (reported in 4%, 0%, 6%, 5%, 0% for placebo, 1 mg, 5 mg, 10 mg, and glimepiride respectively)

Hypoglycemia was not reported with linagliptin or placebo

Hypoglycemia was reported in 4.6% of patients taking glimepiride

Most common:
- Diarrhea (7.7% in LIN 2.5 mg + metformin 1000 mg BID)
- Nasopharyngitis (8.4% in LIN 2.5 mg + MET 500 mg BID)

Hypoglycemia:
- LIN + HD MET – 0%
- LIN + MD MET – 3.5%
- MET 1000 mg BID – 3.4%
- MET 500 mg BID – 1.4%
- LIN 5 mg daily – 0%
- Placebo – 0%

No pancreatitis reported

No clinically meaningful change in body weight was noted in any of the treatment groups

Most common:
- Hypoglycemia (22.7% linagliptin versus 14.8% placebo)
- Severe hypoglycemia occurred in 2.7% linagliptin versus 4.8% placebo

Neither group showed significant changes in weight from baseline

(Continued)
concentrations of 7.5%–11.0% (mean 8.6%) and a body mass index \( \leq 40 \text{ kg/m}^2 \). Patients pretreated with oral antidiabetic therapies underwent a 6-week washout period that included an open-label placebo run-in phase in the last 2 weeks. For treatment-naive patients, only the 2-week run-in phase was required. Eligible subjects were then randomized to receive pioglitazone 30 mg once daily and linagliptin 5 mg once daily or pioglitazone 30 mg once daily and placebo for 24 weeks. The primary endpoint was change from baseline HbA1c, adjusted for baseline HbA1c and

### Table 2 (Continued)

<table>
<thead>
<tr>
<th>Authors and study design</th>
<th>Dose, patients (n)</th>
<th>Study parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gallwitz et al(^7)</td>
<td>Linagliptin 5 mg daily + metformin (n = 764)</td>
<td>Primary: A1c</td>
</tr>
<tr>
<td></td>
<td>Glimepiride 1–4 mg once daily (initially 1 mg) + metformin (n = 755)</td>
<td>Secondary: Hypoglycemic episodes</td>
</tr>
<tr>
<td></td>
<td>Total: 104 weeks</td>
<td>Body weight</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FPG</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A1c &lt; 7.0% and &lt; 6.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A1c lowered by &gt; 0.5%</td>
</tr>
<tr>
<td>Gomis et al(^18)</td>
<td>Linagliptin 5 mg daily + pioglitazone 30 mg daily (n = 259)</td>
<td>Primary: A1c</td>
</tr>
<tr>
<td></td>
<td>Placebo + pioglitazone 30 daily (n = 130)</td>
<td>Secondary: FPG</td>
</tr>
<tr>
<td></td>
<td>Total: 24 weeks</td>
<td>A1c &lt; 7.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A1c lowered by &gt; 0.5%</td>
</tr>
</tbody>
</table>

Abbreviations: AC, active controlled; A1c, glycosylated hemoglobin; ADT, antidiabetic therapy; BID, twice daily; BW, body weight; CV, cardiovascular; DB, double-blind; FPG, fasting plasma glucose; GLIM, glimepiride; HD MET, high dose metformin; LIN, linagliptin; MD MET, moderate dose metformin; MET, metformin; MC, multicenter; NI, noninferiority; NR, not reported; PG, parallel-group; PIO, pioglitazone; PC, placebo-controlled; PP, postprandial plasma glucose; R, randomized; RR, relative risk; SU, sulfonylurea; TZD, thiazolidinediones.
Efficacy results

<table>
<thead>
<tr>
<th></th>
<th>A1c change (%)</th>
<th>FPG change (mg/dL)</th>
<th>PPG change (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linagliptin</td>
<td>−0.16$m$</td>
<td>−2.34$m$</td>
<td>−28.47$m$</td>
</tr>
<tr>
<td>Glimepiride</td>
<td>−0.36$m$</td>
<td>−8.65$m$</td>
<td>−18.74$m$</td>
</tr>
</tbody>
</table>

Notes: a: Treatment difference was 0.20%; P = 0.0004, < 0.0015 (one-sided); b: treatment difference was 6.31 mg/dL; P = 0.0012, < 0.05 (two-sided); c: treatment difference was 9.73 mg/dL; P = 0.0918.

The treatment difference in the adjusted mean change in A1c from baseline was 0.20% and met the prespecified noninferiority criterion of <0.35% with a one-sided α = 0.0125.

A total of 30% of patients achieved an A1c target of <7% with linagliptin versus 35% with glimepiride, while 12% achieved an A1c of <6.5% with linagliptin versus 16% with glimepiride (P < 0.0001). The percentage of patients achieving ≥ 0.5% reduction in A1c was 26% with linagliptin and 34% with glimepiride.

At week 24:

<table>
<thead>
<tr>
<th></th>
<th>A1c change (%)</th>
<th>FPG change (mg/dL)</th>
<th>Body weight change (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linagliptin</td>
<td>−1.06$m$</td>
<td>−32.43$m$</td>
<td>2.3$m$</td>
</tr>
<tr>
<td>Placebo</td>
<td>−0.56$m$</td>
<td>−18.02$m$</td>
<td>1.2$m$</td>
</tr>
</tbody>
</table>

Notes: a: Treatment difference was 0.51%; P < 0.0001; b: treatment difference was −14.41 mg/dL; P < 0.0001; c: treatment difference was 1.1 kg; P = 0.014.

A total of 42.9% of patients achieved an A1c target of <7% with linagliptin versus 30.5% with placebo (P = 0.0051). The percentage of patients achieving ≥0.5% reduction in A1c was 75% with linagliptin and 50.8% with placebo.

At week 102:

<table>
<thead>
<tr>
<th></th>
<th>A1c change (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>−0.8$m$</td>
</tr>
<tr>
<td>Group B</td>
<td>−0.9</td>
</tr>
<tr>
<td>LIN monotherapy</td>
<td>−0.5</td>
</tr>
<tr>
<td>LIN + MET</td>
<td>−0.7</td>
</tr>
<tr>
<td>MET + LIN + SU</td>
<td>−0.7</td>
</tr>
<tr>
<td>LIN + PIO</td>
<td>−1.5</td>
</tr>
</tbody>
</table>

Notes: Coefficient of durability per 78 weeks, 0.14% (P < 0.0001, noninferiority 0.3%).

A total of 42.2% of subjects in group A and 46.1% of those in group B reached the A1c target of <7.0% at week 78 of the extension phase. The percentage of subjects with A1c lowering by ≥0.5% at week 78 was twice that in group B compared with group A (46.9% versus 17.1%, respectively).

Tolerability results

Most common:

- Hypoglycemia (7% linagliptin vs 36% glimepiride; P < 0.0001)
- Nasopharyngitis (16% in both linagliptin and glimepiride)
- Back pain (9% linagliptin versus 8% glimepiride)
- Severe hypoglycemia: one versus 12 patients with linagliptin and glimepiride, respectively
- BW: −1.4 kg linagliptin versus +1.3 kg glimepiride with treatment difference of −2.7 kg (P < 0.0001)
- CV events: 12 (2%) patients with linagliptin versus 26 (3%) patients with glimepiride (RR = 0.46, P = 0.0213)
- One patient experienced pancreatitis with linagliptin

Most common:

- Weight gain: 2.3% with linagliptin + pioglitazone versus 0.8% with pioglitazone + placebo
- Hypoglycemia: 1.2% with linagliptin + pioglitazone vs 0% with pioglitazone + placebo
- BW: mean weight increased in both groups; LIN + PIO was lower than placebo + PIO at baseline (78.3 kg and 82.7 kg, respectively) and at week 24 (80.8 kg and 84 kg, respectively)

Most common:

- Hyperglycemia (24.4% group A versus 20.5% group B)
- Hypoglycemia (LIN + MET + SU 11%, LIN + MET 2.1%, LIN monotherapy 0.5%, LIN + PIO 0.2%)
- Severe hypoglycemia: 0.6% overall
- No clinically relevant change in body weight observed
- Pancreatitis: 4 patients in group A (0.2% of the overall treatment set experienced pancreatitis) (2 acute cases and 4 chronic cases)

baseline antidiabetic therapy, after 24 weeks of treatment. At the end of the study, the adjusted mean change in HbA1c from baseline for linagliptin plus pioglitazone was −1.06% compared with −0.56% for placebo plus pioglitazone. The placebo-corrected difference in HbA1c was 0.51%. Changes in fasting plasma glucose were assessed as a secondary endpoint, showing a significantly greater reduction for linagliptin plus pioglitazone than for placebo plus pioglitazone. Changes in postprandial plasma glucose were not addressed in this study (see Table 2).
Open-label extension: linagliptin monotherapy or in combination with other oral antidiabetic therapies

A 78-week open-label extension conducted by Gomis et al evaluated participants who had previously completed one of the four 24-week, randomized, double-blind, placebo-controlled parent trials. These subjects received either linagliptin monotherapy, linagliptin plus metformin, linagliptin plus metformin and sulfonylurea, or linagliptin plus pioglitazone. All patients receiving one of these treatments during a previous trial continued the same treatment for an additional 78 weeks (n = 1532). Those patients previously treated with placebo were switched to linagliptin monotherapy (n = 589). Overall, the cohort of patients had a mean age of 57.7 years and mean baseline HbA1c of 7.5%. This extension study was conducted primarily to assess the long-term safety and tolerability of linagliptin. Secondary efficacy outcomes evaluated the changes in HbA1c and fasting plasma glucose from baseline to 102 weeks. In participants randomized to treatment with linagliptin in the four previous trials, the mean change from baseline HbA1c during the initial 24 weeks of treatment was −0.8%. This was maintained over the 78 weeks of the extension study, with a change from baseline HbA1c of −0.8%. The largest observed reduction in HbA1c from baseline to week 102 was in the group receiving linagliptin plus pioglitazone at −1.5%. This was followed by those patients receiving metformin and metformin plus a sulfonylurea in combination with linagliptin (−0.7%). Lastly, patients receiving linagliptin monotherapy showed a reduction of 0.5% at week 102. Similarly, fasting plasma glucose values already reduced during the previous trials further decreased during the extension period. In subjects randomized to placebo in the previous trials and switched to linagliptin monotherapy in the extension phase, the change in mean HbA1c was −0.90%. Fasting plasma glucose values also decreased from baseline over the study period (see Table 2).

Safety and tolerability

Most adverse events with linagliptin were considered to be mild to moderate in nature. Adverse reactions that occurred in ≥2% of patients treated with linagliptin included nasopharyngitis, diarrhea, cough, urinary tract infection, and hypertriglyceridemia (in combination with sulfonylurea therapy), hyperlipidemia, and weight increase (in combination with pioglitazone). Weight changes were reported or addressed in each of the studies above. No significant changes with regard to body weight were found when linagliptin was given as monotherapy. With regard to sulfonylurea therapy, two of the studies revealed an increase in body weight in patients treated with glimepiride versus those receiving linagliptin. However, in a study in which all patients received metformin and sulfonylurea therapy and were then randomized to placebo or linagliptin, no significant changes in body weight were seen. When patients received pioglitazone and either placebo or linagliptin, both groups showed an increase in body weight from baseline. The amount of weight gain was larger in patients receiving linagliptin, but the mean weight for patients receiving linagliptin was lower than that in patients receiving placebo at baseline. In general, linagliptin showed a low propensity to cause hypoglycemia. When used as monotherapy, no patients experienced hypoglycemia in the two studies reviewed. One study reviewing linagliptin as monotherapy versus placebo reported hypoglycemia occurring in one patient in each group. When combined with metformin and sulfonylurea, a higher percentage of patients receiving linagliptin experienced hypoglycemia versus placebo. However, a smaller percentage of patients experienced severe hypoglycemia when compared with placebo. Three studies discussed or reported the occurrence of pancreatitis. One study reported zero cases while another study reported one case of pancreatitis in a patient receiving linagliptin. A 78-week, open-label extension study, which included 2121 subjects, reported four cases of pancreatitis in patients who had received linagliptin for a total of 102 weeks, with two cases being acute and two chronic. This was an incidence of 0.2% in the overall treated set. According to the prescribing information, pancreatitis was reported more often in patients treated with linagliptin (21.9 per 10,000 patient years) versus placebo (eight per 10,000 patient years). One study prospectively assessed cardiovascular safety for linagliptin versus sulfonylurea (e.g. glimepiride). Major cardiovascular events occurred in 2% of patients treated with linagliptin and 3% treated with glimepiride (P = 0.0213). This finding was mainly attributable to a significantly lower number of nonfatal strokes with linagliptin compared with glimepiride, without any relation to hypoglycemia.

Discussion

Data from the clinical trials suggest that linagliptin administered as monotherapy or in combination with other antidiabetic therapies improves HbA1c and reduces fasting plasma glucose. When used as monotherapy, linagliptin resulted in a placebo-corrected change in HbA1c ranging from −0.28% to 0.69%. When linagliptin was added to metformin or metformin and a sulfonylurea, similar HbA1c reductions ranging from 0.39% to 0.75% were observed. When comparing linagliptin with glimepiride as add-on therapy
to metformin, a numerically greater response was seen with glimepiride, but this was not statistically significant. However, when linagliptin was used in combination with pioglitazone, larger reductions in placebo-corrected HbA1c of 1.06% were seen. Those studies that evaluated the impact of linagliptin therapy on postprandial plasma glucose also reported an improvement. When used as monotherapy, linagliptin decreased postprandial plasma glucose in the range of 27.2–57.7 mg/dL, and when used in combination with metformin, postprandial plasma glucose decreased by 66.7 mg/dL. With this, the data suggest linagliptin used as monotherapy or in combination with other antidiabetic therapies offers improvement in glycemic control. Specific populations that may particularly benefit from linagliptin therapy should also be considered. In patients experiencing renal impairment precluding the use of metformin, linagliptin may have a niche in managing glycemia because it does not require dose adjustment in renal compromise. Several of the studies discussed in this review stratified the change in HbA1c according to the baseline value. Reduction in HbA1c was greater in patients with a baseline HbA1c > 9%, offering another possible niche for linagliptin therapy.

DPP-4 inhibitors as a class are generally well tolerated. A minimal risk of hypoglycemia when used as monotherapy and lack of weight gain are some of the desirable characteristics of this class of medications. Overall, linagliptin has been shown to be well tolerated, with adverse events similar to others within its class. It is important to note that although linagliptin offers a low risk of hypoglycemia, this risk increases when this agent is combined with secretagogue therapy. Linagliptin used in combination with thiazolidinediones also offers augmentation of weight gain. Pancreatitis is also of concern and is a class effect of DPP-4 inhibitors, although the risk of the condition seems very low with this medication. A long-term safety and efficacy study evaluated linagliptin therapy in over 2000 patients for a total of 102 weeks and found an overall incidence of 0.2%. However, recent discussions have noted that the prevalence of pancreatitis among patients with type 2 diabetes is similar to that seen with incretin hormones. A study published in 2009 by Noel et al found that patients with type 2 diabetes had an almost three-fold greater risk of pancreatitis than those patients without diabetes. This information suggests that there may not be an increased risk of pancreatitis with incretin therapy.

Linagliptin has several differences compared with the other currently available DPP-4 inhibitors. It has a long half-life and undergoes less renal excretion, avoiding the need for dose adjustments in patients with renal impairment. However, to date, there are no head-to-head studies comparing the efficacy of this agent with other DPP-4 inhibitors in its class.

Conclusion
Linagliptin is a newly approved DPP-4 inhibitor for use as a once-daily oral medication in the treatment of type 2 diabetes. The use of linagliptin as monotherapy or in combination with metformin or pioglitazone led to reductions in HbA1c and fasting plasma glucose after 12–24 weeks of therapy. This improvement in glycemic control was shown to be maintained for up to 102 weeks. Linagliptin appears to be well tolerated in most patients. It is generally considered to be weight neutral, unless used in combination with a thiazolidinedione, and has a low risk of hypoglycemia.

Disclosure
The authors have no conflict of interest to disclose with regard to the content of this article.

References


